Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 6, 1997, Pages 1031-1035

  Evans, R C ^a   Clarke, L ^a   Heath, P ^a   Stephens, S ^b   Morris, A I ^b   Rhodes, J M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INTERLEUKIN 6; MESALAZINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESISTANCE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030834037     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00251.x     Document Type: Article

References (15)

1. Rhodes JM. Medical management of ulcerative colitis. In: Allan RN, Keighley MRB. Alexander-Williams J, Hawkins C, eds. Inflammatory Bowel Diseases. Edinburgh: Churchill Livingstone, 1990.
2. Sartor RB. Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-9.
3. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-17.
4. Braegger CP, Nicholls S, Murch SH. Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation [see comments]. Lancet 1992; 339: 89-91.
5. Warren BF. Anti TNF alpha treatment of a model of human ulcerative colitis. Gut 1994; 35(SuppI. 2): F199.
6. van Dulleman HM, van Deventer SJH, Holmes DW. et al. Treatment of Crohn's disease with anti-tumour necrosis factor monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
7. Stephens S, Emtage S, Vetterlein O, et al Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotype responses. Immunology 1995: 85: 668-74.
8. Ward PS, Woodger SR. Bodmer M. Foulkes R. Anti-tumour necrosis factor alpha monoclonal antibodies (anti-TNF Mab) are therapeutically effective in a model of colonie inflammation. Brit J Pharmacol 1993; 110: 77P.
9. Truclove SC, Wilts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955: 2: 1041-8.
10. Powell-Tuck JA. Day DW. Bucknell NA. Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-7.
11. Rankin ECC. Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42.
12. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997: 349: 521-4.
13. Sheron N, Lau JN, Hofmann J, Williams R. Alexander GJ. Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans. Clin Exp Immunol 1990: 82: 427-8.
14. LoBuglio AF, Wheeler RH, Trang J. Mouse human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci 1989; 86: 4220-4.
15. Santos J, Baudet S. Casellas F, Guarner L, Vilaseca J, Malagelada JR. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995; 20: 285-9.